Quarterly report [Sections 13 or 15(d)]

Asset Purchase and Merger Agreements (Narrative) (Details)

v3.25.3
Asset Purchase and Merger Agreements (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 21 Months Ended
Jul. 15, 2024
Jun. 27, 2024
Jul. 31, 2023
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Dec. 31, 2024
Business Combination [Line Items]                  
Other       $ 3,208   $ 3,208   $ 3,208 $ 3,612
Fair value of supplies received by partner company expensed to research and development           0 $ 2,509    
Assets held for sale       $ 0   $ 0   $ 0 1,165
Mustang | UBriGene                  
Business Combination [Line Items]                  
Consideration Transferred   $ 4,700 $ 6,000            
Repurchased assets on relative fair value basis   2,200              
Consideration Transferred   1,400              
Gain on sale of asset     1,400            
Expenses related to transactions having to do with sale of assets.     $ 300            
Upfront payment   100              
Subsequent amount   $ 1,300              
Subsequent payment due period   12 months              
Asset acquisition consideration, threshold net assets considered for delay in subsequent payment   $ 20,000              
Interest rate on outstanding liability   5.00%              
Net Receivable from uBriGene   $ 3,300              
Other                 1,300
Fair value of supplies received by partner company expensed to research and development   2,500              
Assets held for sale   $ 2,200             $ 1,200
Subsequent payment extended due period   6 months              
Urica                  
Business Combination [Line Items]                  
Percentage of equity to be held 35.00%                
Urica's equity position       15.00%   15.00%   15.00%  
Repurchase option liability           $ 2,600      
Urica | Asset Purchase, Royalty And Related Agreements With Crystalis                  
Business Combination [Line Items]                  
Consideration Transferred $ 6,400                
Percentage of royalty on future net sales 3.00%                
Urica's equity position 15.00%     15.00%   15.00%   15.00%  
Capitalization in equity securities $ 150,000                
Reimbursement for clinical costs 600                
Amount of minimum qualified financing required $ 120,000                
Assets Sold under Agreements to Repurchase, Accretion Expense       $ 700   $ 1,300      
Urica | Crystalys Therapeutics, Inc                  
Business Combination [Line Items]                  
Assets Sold under Agreements to Repurchase, Accretion Expense         $ 300   300    
Avenue | InvaGen | Avenue Share Repurchase Agreement                  
Business Combination [Line Items]                  
Percentage of contingent fee payable       7.50%   7.50%   7.50%  
Contingent fee payable from proceeds of future financing       $ 4,000   $ 4,000   $ 4,000  
Payments of milestones           $ 200 $ 700 $ 1,400